US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

Clene Inc

us-stock
To Invest in {{usstockname}}
us-stock
$8.1 -0.2203(-22.03%) CLNN at 04 Dec 2025 04:28 PM Packaged Foods
Lowest Today 7.21
Highest Today 9.5
Today’s Open 9.295
Prev. Close 9.26
52 Week High 13.50
52 Week Low 2.28
Day’s Range: Low 7.21 High 9.5
52-Week Range: Low 2.28 High 13.50
1 day return -
1 Week return -29.21
1 month return -34.36
3 month return +21.14
6 month return +79.6
1 year return +71.9
3 year return +568.51
5 year return -35.82
10 year return -

Institutional Holdings

NT Ext Equity Mkt Idx Fd - DC - NL - T2 1.81

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.65

BNYM Mellon SL Market Completion UC1 0.16

BNYM Mellon NSL Mkt Completion Fund Inst 0.01

Market Status

Strong Buy: 3

Buy: 3

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 95.69 M

PB Ratio 7.8325

PE Ratio 0.0

Enterprise Value 115.28 M

Total Assets 27.34 M

Volume 3457894

Company Financials

Annual Revenue FY23:718000 0.7M, FY22:473000 0.5M, FY21:723000 0.7M, FY20:206000 0.2M, FY19:0 0.0M

Annual Profit FY23:628000 0.6M, FY22:447000 0.4M, FY21:434000 0.4M, FY20:141000 0.1M, FY19:0 0.0M

Annual Net worth FY23:-40385000 -40.4M, FY22:-15279000 -15.3M, FY21:-9740000 -9.7M, FY20:-19277000 -19.3M, FY19:-16270000 -16.3M

Quarterly Revenue Q3/2025:15000 0.0M, Q2/2025:27000 0.0M, Q1/2025:81000 0.1M, Q3/2024:87000 0.1M, Q2/2024:91000 0.1M

Quarterly Profit Q3/2025:15000 0.0M, Q2/2025:27000 0.0M, Q1/2025:61000 0.1M, Q3/2024:69000 0.1M, Q2/2024:73000 0.1M

Quarterly Net worth Q3/2025:-8777000 -8.8M, Q2/2025:-7419000 -7.4M, Q1/2025:-751000 -0.8M, Q3/2024:-7986000 -8.0M, Q2/2024:-6785000 -6.8M

Fund house & investment objective

Company Information Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Organisation Packaged Foods

Employees 75

Industry Packaged Foods

CEO Mr. Robert Etherington MBA

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right